Peer-reviewed veterinary case report
Toceranib phosphate treatment for cats with visible mammary cancer
By Del Portillo Miguel, Isabel et al.·Published in Journal of feline medicine and surgery·2024·Hospital for Small Animals, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the efficacy and safety of toceranib phosphate in cats with macroscopic mammary adenocarcinoma.
- Species:
- cat
Plain-English summary
A group of 17 cats with advanced mammary tumors were treated with toceranib phosphate, a medication aimed at managing this aggressive cancer. After one month, 12 of the cats showed some improvement, with one cat experiencing a complete response and five showing partial responses. While some cats did experience mild side effects, these were manageable, and only one cat had a more serious reaction that improved after adjusting the dose. Overall, the treatment provided a new option for cats with this challenging condition, with an average survival time of about 145 days.
People also search for: cat mammary tumor treatment · toceranib phosphate for cats · cat cancer survival rates
Abstract
OBJECTIVES: Mammary tumours in cats are biologically aggressive. The standard of care relies upon wide surgical resection. Chemotherapy has been described in the macroscopic disease setting; however, limited efficacy has been shown. The aim of this study was to assess the efficacy of toceranib phosphate in macroscopic feline mammary tumours (FMTs). METHODS: A total of 17 cats with cytologically or histopathologically confirmed mammary adenocarcinoma (gross disease) were prospectively enrolled. Toceranib phosphate was administered at a median dose of 2.77 mg/kg (range 2.3-3.2) PO q48 h. No corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) were administered. Toxicity was graded according to Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) v1.1 criteria. The response was assessed after 1 month, following Response Evaluation Criteria In Solid Tumours (RECIST) criteria. RESULTS: Toxicity was observed in eight cats, with most instances being grade 1 or 2, which were managed with supportive care. Only one cat experienced grade 3 toxicity (anorexia), which resolved after a dose reduction. Clinical benefit was seen in 12 (64.7%) cats and an objective response was seen in six (35.2%) cats. One cat experienced complete response, five had partial response, six had stable disease and five had progressive disease. One cat showed distant progression (malignant pleural effusion) despite continued partial remission of the primary tumour. The median progression-free survival and median overall survival time were 91 days (range 30-158) and 145 days (range 31-234), respectively. CONCLUSIONS AND RELEVANCE: Toceranib phosphate showed clinical benefit and a good safety profile in advanced or recurrent FMTs, offering a new alternative in the treatment of this disease; however, further prospective and randomised studies are required to further assess its efficacy. Interestingly, one cat developed distant metastases while the primary tumour showed partial response, suggesting that primary tumour and metastatic disease may not sustain the same sensitivity to toceranib.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39212426/